Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib in relapsed/refractory mantle cell lymphoma after BTK inhibitor failure
NCT05716087Phase 2Active, not recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rocbrutinib in mantle cell lymphoma (MCL), sponsored by Lupeng Pharmaceutical. Primary endpoint: Overall Response Rate at 24 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
rocbrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05716087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716087.